Prognostic Factors and the Impact of Various Management of Acute Myeloid Leukemia in Real Life Condition
Active, not recruiting
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Drug: intensive chemotherapy
- Registration Number
- NCT03284593
- Lead Sponsor
- University Hospital, Toulouse
- Brief Summary
The treatment of older patients with acute myeloid leukemia that is secondary to previous myelodysplastic syndrome, myeloproliferative neoplasm, or prior cytotoxic exposure remains unsatisfactory. We compared patients treated with intensive chemotherapy or azacitidine within two centres.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 199
Inclusion Criteria
- patients with acute myeloid leukemia
Exclusion Criteria
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Azacitidine group Azacitidine patients treated with azacitidine intensive chemotherapy group intensive chemotherapy patients treated with intensive chemotherapy
- Primary Outcome Measures
Name Time Method Survival 2 years Survival times
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (2)
University Hospital Bordeaux
🇫🇷Bordeaux, France
University Hospital Toulouse
🇫🇷Toulouse, France